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Abstract  
 
For more than four decades, combination chemotherapy (co-chemotherapy) has been 
employed as a means to increase the effectiveness of chemotherapy regiments. The aim of our 
research is to investigate the activity of Moringa oleifera L. (tanaman kelor) ethanolic extract 
(MEE) as a co-chemotherapy agent with 5-fluorouracil (5-FU) on WiDr colon cancer cell line. 
Evaluation of MEE potency as a co-chemotherapy agent with 5-FU was based on cytotoxic 
activity based on percent cell viability via MTT assay, and based on apoptosis observation via 
the double staining method using acrydin orange–ethidium bromide (AE) as the staining 
reagent.Cytotoxicity evaluation of single treatment using concentrations of 5, 20, 50, 100,125, 
and 250 µg/ml of MEE reduced cell viability 24 hours post-treatment. 5, 50, and 250 µg/ml of 
MEE was chosen as the combination concentrations with 1000 µM 5-FU. MTT assay 24 hours 
and 48 hours post-combination treatment showed significant cell viability reduction in 
comparison to those of single treatments. Apoptosis observation using the double staining 
method shows the presence of apoptotic cells 48 hours post combination treatment. MEE is a 
potential co-chemotherapy agent by increasing the sensitivity of WiDr colon cancer cell line 
towards 5-FU. 
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INTRODUCTION 
 
Of the many cancer therapies, 
chemotherapy remains the conventional and main 
method to prescribe. Chemotherapy involves the 
use of synthetic chemical agents to suppress cancer 
cell proliferation or to destroy cancer cells. 5-
Fluorouracil (5-FU) is currently dubbed as the 
main chemotherapy agent for the treatment of 
colon cancer. However, 5-FU is also notorious for 
its adverse side effects and is prone to cause 
resistance on cancer cells (Kodach et al, 2006). To 
solve this problem, combination chemotherapy 
(co-chemotherapy) is a viable option to delve in to. 
Co-chemotherapy is an effort to reduce the 
side effects of chemotherapy by introducing 
additional anticancer agent(s) within the therapy 
regiment(s). When the interaction between the two 
agents is synergistic, co-chemotherapy can 
increase the potency of the chemotherapy agent to 
cancer cell proliferation (Brenner, 2002). Moringa 
oleifera L. is a plant known to have anticancer 
activity. 
Many research have reported the anticancer 
activity of Moringa oleifera L. This plant contains 
a unique combination of molecules called 
isothiocyanates and glucocynolates. It has been 
reported that isothiocyanates have 
chemopreventive properties by modifying the 
metabolic processes of carcinogenesis through 
inhibition of phase 1 metabolic enzymes and/or 
induction of phase 2 metabolic enzymes (Hetch, 
2009). Benzyl isothiocyanate, an analogue of 
isothiocyanate, has shown apoptotic activity on 
ovarian cancer and G2/M cell cycle arrest on 
pancreatic cancer cells (Srivastava and Singh, 
2004).  
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Bharali et al (2003) have also reported 
ethanolic extracts of Moringa oleifera L. is a 
potential chemopreventive agent in suppressing 
carcinogenesis due to toxic chemicals exposure. 
Based on those research, it can be hypothesized 
that ethanolic extracts of Moringa oleifera L. is a 
potential co-chemotherapy agent with 5-FU 
 
MATERIALS AND METHOD 
 
Plant sample and extract preparation– 
Moringa oleifera L.  
Was obtained from nature in the Yogyakarta 
area, which was then officially determined by the 
Biological Pharmaceutics Department of the 
Faculty of Pharmacy, Universitas Gadjah Mada. 
The extract was then prepared by using 95% 
ethanol as the solvent for maceration. The 
macerate was then strained and a dilute extract was 
obtained. The extract was concentrated using a 
rotary evaporator continued with freeze drying to 
further eliminate traces of ethanol. The 
concentrated extract was then dissolved in DMSO 
(Sigma) for treatment. 
 
WiDr cell preparation   
WiDr colon cancer cell line used in this 
study was obtained from the collection of Cancer 
Chemoprevention Research Center of the Faculty 
of Pharmacy Universitas Gadjah Mada. WiDr was 
cultured in RPMI growth medium (Gibco) 
containing 10% v/v fetal bovine serum (Gibco), 
1% v/v penicillin-streptomycin (Gibco), and 
0,05% v/v fungizone (Gibco). Cell was cultivated 
from the culture dish using tripsin-EDTA 0,25% 
v/v (Gibco). 
 
Cytotoxicity assay procedure  
Cultivated cells were transferred into 96-
well plates (Iwaki) then incubated for until 
confluent. Once the cells are confluent, treatment 
was conducted in accordance to the pre-calculated 
concentrations. MTT reagent was added 24 hours 
or 48 hours post-treatment (depending on the 
experiment), then SDS 10% v/v in HCl was added 
4 hours later. Following an overnight incubation 
period, the cell’s absorbance was read using 
microplate reader. 
 
Apoptosis detection procedure  
Cover slips (Iwaki) were placed in 24-well 
plate (Iwaki) then cells are transferred on to them, 
then incubated until confluent. The confluent cells 
are then treated with the selected dosage according 
to the co-chemotherapy MTT results. Once 
incubated for 48 hours post-treatment, the cover 
slips are removed from the wells and stained with 
10 µL of Acrydin orange-Ethidium bromide (AE) 
to stain the cells. The stained cells are observed 
and recorded under fluorescent microscope. 
 
RESULTS  
 
Cytotoxicity assay of single MEE treatment 
and 5-FU – MEE combination treatment 
The MTT assay results show that MEE 
increases WiDr cell’s sensitivity towards 5-FU. 
MTT assay of MEE as a single agent shows 
reduced cell viability due to treatment (Figure 1). 
From this result, concentrations of 5, 50, and 250 
µg/ml MEE was chosen as the combination 
concentrations which represents the whole range 
of data. Co-chemotherapy treatment using 1000 
µM 5-FU with 5, 50, and 250 µg/ml MEE shows 
further cell viability reduction (Figure 2). 
Continued co-chemotherapy treatment for 48 hours 
gave the best results (Figure 2). Percent cell 
viability of 50% (IC50 value) was obtained for 
concentration of 1000 µM 5-FU with 50 µg/ml 
MEE.  
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Figure 1. Cytotoxicity evaluation of single MEE treatment on WiDr cells. Assay was conducted by incubating WiDr cell 
in 96-well plate for 24 hours to normalize. Treatment series of 5-250 g/ml was administered followed by 
further incubation for 24 hours as described in the methodology. Cell viability data was obtained thourgh 
convertion of absorbanse from formazan cyrstal formation due MTT treatment, as described in the 
methodology.  Viabilty profile is presented from the mean  standard error (SE) from 3 experiments. The 
treatment of MEE on WiDr resulted in reduced cell viability. 
 
Figure 2. Cytotoxicity evaluation of combination treatment post 24 hours and 48 hours treatment. Assay was conducted 
by incubating WiDr cell in 96-well plate for 24 hours to normalize. Combination treatment series of 5, 50, 
250 g/ml MEE with 1000 M was administered followed by further incubation for 24 hours or 48 hours as 
described in the methodology. Cell viability data was obtained thourgh convertion of absorbanse from 
formazan cyrstals formation due MTT treatment, as described in the methodology. As comparison, single 
2500uM 5-FU and EEM data is also presented. Viabilty profile is presented from the mean  standard error 
(SE) from 3 experiments. The combination treatment of MEE – 5-FU for 24 hours on WiDr resulted in 
greater cell viability reduction compared to single treatments. Further cell viability reduction was observed  
post 48 hours treatment.  
 
  
 
 
 
 
 
 
 
 
These cell deaths were most likely due to 
apoptosis. To ascertain this postulation, we 
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continued further with our investigation and 
conducted apoptosis detection assay using the 
double staining method. 
 
 
 
 
 
 
Detection of apoptotic cells using double 
staining method  
Results of apoptosis detection show that 
reduction of cell viability post treatment was due 
to apoptosis. In the control (Fig 3(A)), only green 
fluorescent cells are present indicating the absence 
of apoptotic cells. It is in the treatment cells that 
the occurrence of apoptosis was observed. At 
combination concentration of 1000 uM 5-FU with 
50 ug/ml MEE, orange fluorescent cells develop 
(Figure 3B – 3D).  
 
 
             
Figure 3. (A) control (B) – (D) results of double staining following 48 hours post co-chemotherapy 
treatment concentration of 1000 µM 5-FU with 50 µg/ml MEE. Cells were seeded on cover slips 
in 24-well plates and treated with combination of 1000 µM 5-FU with 50 µg/ml MEE. After 48 
hours of incubation each well was washed with PBS, cover slips removed, then treated with 
ethidium bromide – acrydin orange fluorescent dye. Living cells emit green fluorescence while 
apoptotic cells emit orange fluorescence (arrowed). 
 
 
DISCUSSION 
 
Our hypothesis, that MEE has a potential as 
a co-chemotherapy agent with 5-FU in colon 
cancer treatment, was confirmed by the research 
findings. MTT assay of single MEE treatment 
show reduction of cell viability. Further and more 
significant cell viability reduction was observed on 
the combination treatment cell viability profile.  
The mechanism of action of 5-FU – MEE 
combination is due to enhancement of cancer cell 
cytotoxicity. As reported by De Angelis et. al. 
(2006) 5-FU damages the DNA double strand and 
induce apoptosis of colon cancer cells, which is 
mediated by the p53 protein. Benzyl 
isothiocyanate (BITC) and phenethyl 
isothiocyanate (PEITC), the principle anti-
tumoregenesis compounds in Moringa oleifera L., 
have been previously reported to induce apoptosis. 
BITC up-regulate the p21 protein, resulting in cell 
apoptosis (Zhang, R., et. al., 2009).  PEITC causes 
cell apoptosis by down-regulating Bcl-2/XIAP and 
through the mitochondrial pathway (Lee, J.W., and 
Cho, M.K., 2008). Our research findings are in 
accordance to these previously reported studies. 
Our data showed that cell viability reduction 
is apparently dosage dependent. As shown in 
Figure 1, each increase in treatment concentration 
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correlates with reduction in cell viability. An even 
more significant cell viability reduction profile 
was observed from co-chemotherapy treatment 
(Figure 2). Results show that combination 
treatment enhances the effectiveness of 5-FU in 
reducing cell viability. The combination treatment 
post 48 hours is particularly noteworthy. Even 
though the treatment dosage (1000 uM 5-FU with 
50 ug/ml) was much lower than the single 5-FU 
cytotoxicity profile of 2500 uM (resulting in 
63.8% viable cells), it was able to result in percent 
cell viability of 47.8 %. To further reaffirm that the 
reduced cell viability was due to apoptosis, we 
conducted the double staining apoptosis assay 
using ethidium bromide – acrydin orange. As 
shown in figure 3, treatment of 1000 uM 5-FU 
with 50 ug/ml resulted in the appearance of 
apoptotic bodies. 
To explore the underlying cytotoxicity and 
apoptosis induction mechanism, further research is 
needed. Flow cytometric analysis is needed to 
determine the effect on cell cycle progression. 
Western Blotting should also be conducted to 
ascertain which proteins are involved.  
 
CONCLUSION 
 
The anti-tumoregenesis activity of 5-FU is 
enhanced through combination with MEE through 
increased cytotoxicity and apoptosis induction. 
MEE has potential to become a co-chemotherapy 
agent with 5-FU.  
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